GENZ has restarted production of Fabrazyme and Cerezyme at the Allston plant. Will they be allowed to sell that production when they eventually satisfy the FDA?
Key word in your question is 'satisfy', meaning - will the FDA be satisfied with Cerezyme and Fabrazyme that were produced before reinspection? I think it will cause the reinspection is probably more about the manufacturing issue detailed in a warning letter that was issued in Feb and not about the viral contamination. Key question is - when. Of course GENZ will eventually get these issues taken care of, but meanwhile, they are losing time, money, and credibility and competitors are enjoying a tailwind.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.